Insys Therapeutics Inc was incorporated in Delaware in June 1990. The Company is a commercial-stage specialty pharmaceutical company. It develops and commercializes supportive care products. The Company has two marketed products Subsys and Dronabinol SG Capsule. Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients and Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment of chemotherapy-induced nausea and vomiting, or CINV, and anorexia associated with weight loss in patients with AIDS. It markets Subsys through an incentive-based sales model. Dronabinol SG Capsule is a dronabinol soft gelatin capsule that is a generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS, offered in 2.5, 5.0 and 10.0 milligram dosages. The Company produces the Active Pharmaceutical Ingredient (API) for Dronabinol SG Capsule at its U.S.-based, state-of-the-art dronabinol manufacturing facility. The Company is subject to regulation by the FDA.